MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
PetIQ Total Liabilities 2011-2025 | PETQ
Annual Total Liabilities PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 478 M | 344 M | 174 M | 36 M | 40.3 M | 46.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 478 M | 36 M | 186 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
449 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.22 | 2.4 % | $ 131 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
10.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
218 M | $ 2.64 | -0.94 % | $ 1.38 B | Canada |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
244 M | $ 4.36 | -2.9 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
13.2 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 12.17 | -2.05 % | $ 623 M | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | $ 21.52 | -0.32 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
227 M | $ 6.7 | -2.9 % | $ 416 M | USA |
 |
Harrow Health
HROW
|
242 M | $ 50.91 | 1.64 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
7.14 M | $ 1.21 | -6.04 % | $ 21.1 M |  China |
 |
Neoleukin Therapeutics
NLTX
|
36.5 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.71 | -4.42 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
113 M | $ 5.17 | -2.09 % | $ 681 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.17 | -0.49 % | $ 2.62 B | Canada |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 3.95 | -4.13 % | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
30.9 M | $ 0.82 | -5.73 % | $ 19.1 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 3.65 | 1.23 % | $ 4.53 M | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 26.29 | -0.83 % | $ 1.22 B | USA |
 |
Sundial Growers
SNDL
|
216 M | $ 1.73 | -0.29 % | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
9.51 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
5.33 B | $ 13.68 | -0.98 % | $ 1.88 B | USA |
 |
ProPhase Labs
PRPH
|
24 M | $ 0.46 | -12.02 % | $ 7.29 M | USA |
 |
Veru
VERU
|
28.1 M | $ 2.26 | -5.83 % | $ 305 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 1.56 | -8.24 % | $ 6.73 M | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.38 | -2.88 % | $ 132 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
148 M | $ 9.34 | -6.09 % | $ 663 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
51.4 M | $ 5.75 | -1.63 % | $ 235 M | USA |
 |
SCYNEXIS
SCYX
|
55.4 M | $ 0.63 | 7.31 % | $ 30.1 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
977 M | $ 9.36 | -2.49 % | $ 5.78 B | Canada |
 |
TherapeuticsMD
TXMD
|
14 M | $ 1.75 | 0.57 % | $ 18.3 M | USA |